Replication and cytopathic effect of oncolytic vesicular stomatitis virus in hypoxic tumor cells in vitro and in vivo

Journal of Virology

Volumn 78, Issue 17, 2004, Pages 8960-8970

  Connor, John H ^a   Naczki, Christine ^a   Koumenis, Costas ^a   Lyles, Douglas S ^a  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DNA; INITIATION FACTOR 2; INITIATION FACTOR 2ALPHA; INITIATION FACTOR 4E; MESSENGER RNA; ONCOLYTIC VIRUS; PROTEIN; RNA; UNCLASSIFIED DRUG; VIRUS PROTEIN;

ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER THERAPY; CELL KILLING; CONTROLLED STUDY; CYTOPATHOGENIC EFFECT; DEPHOSPHORYLATION; DNA SYNTHESIS INHIBITION; HUMAN; HUMAN CELL; HYPOXIA; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; PROGENY; PROTEIN PHOSPHORYLATION; PROTEIN SYNTHESIS INHIBITION; RNA SYNTHESIS; RNA TRANSLATION; STRESS; TUMOR CELL; TUMOR HYPOXIA; VESICULAR STOMATITIS VIRUS; VIRUS CELL INTERACTION; VIRUS INFECTION; VIRUS REPLICATION; VIRUS RESISTANCE;

ANIMALS; APOPTOSIS; CELL HYPOXIA; CYTOPATHOGENIC EFFECT, VIRAL; EUKARYOTIC INITIATION FACTORS; HELA CELLS; HUMANS; MICE; MICE, NUDE; NEOPLASM TRANSPLANTATION; NEOPLASMS; RNA, MESSENGER; RNA, VIRAL; TRANSPLANTATION, HETEROLOGOUS; VESICULAR STOMATITIS-INDIANA VIRUS; VIRUS REPLICATION;

EID: 4143126659     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/JVI.78.17.8960-8970.2004     Document Type: Article

References (39)

1. Ahmed, M., M. O. McKenzie, S. Puckett, M. Hojnacki, L. Poliquin, and D. S. Lyles. 2003. Ability of the matrix protein of vesicular stomatitis virus to suppress beta interferon gene expression is genetically correlated with the inhibition of host RNA and protein synthesis. J. Virol. 77:4646-4657.
2. Andreansky, S. S., B. He, G. V. Gillespie, L. Soroceanu, J. Markert, J. Chou, B. Roizman, and R. J. Whitley. 1996. The application of genetically engineered herpes simplex viruses to the treatment of experimental brain tumors. Proc. Natl. Acad. Sci. USA 93:11313-11318.
3. Arsham, A. M., J. J. Howell, and M. C. Simon. 2003. A novel hypoxia-inducible factor-independent hypoxic response regulating mammalian target of rapamycin and its targets. J. Biol. Chem. 278:29655-29660.
4. Balachandran, S., and G. N. Barber. 2004. Defective translational control facilitates vesicular stomatitis virus oncolysis. Cancer Cell 5:51-65.
5. Balachandran, S., and G. N. Barber. 2000. Vesicular stomatitis virus (VSV) therapy of tumors. IUBMB Life 50:135-138.
6. Balachandran, S., M. Porosnicu, and G. N. Barber. 2001. Oncolytic activity of vesicular stomatitis virus is effective against tumors exhibiting aberrant p53, Ras, or myc function and involves the induction of apoptosis. J. Virol. 75:3474-3479.
7. Bell, J. C., B. Lichty, and D. Stojdl. 2003. Getting oncolytic virus therapies off the ground. Cancer Cell 4:7-11.
8. Bergmann, M., I. Romirer, M. Sachet, R. Fleischhacker, A. Garcia-Sastre, P. Palese, K. Wolff, H. Pehamberger, R. Jakesz, and T. Muster. 2001. A genetically engineered influenza A virus with ras-dependent oncolytic properties. Cancer Res. 61:8188-8193.
9. Binley, K., Z. Askham, L. Martin, H. Spearman, D. Pay, S. Kingsman, and S. Naylor. 2003. Hypoxia-mediated tumour targeting. Gene Ther. 10:540-549.
10. Brahimi-Horn, C., E. Berra, and J. Pouyssegur. 2001. Hypoxia: the tumor's gateway to progression along the angiogenic pathway. Trends Cell Biol. 11:S32-S36.
11. Brown, J. M. 2002. Tumor microenvironment and the response to anticancer therapy. Cancer Biol. Ther. 1:453-458.
12. Connor, J. H., and D. S. Lyles. 2002. Vesicular stomatitis virus infection alters the eIF4F translation initiation complex and causes dephosphorylation of the eIF4E binding protein 4E-BP1. J. Virol. 76:10177-10187.
13. Dubensky, T. W., Jr. 2002. (Re-) Engineering tumor cell-selective replicating adenoviruses: a step in the right direction toward systemic therapy for metastatic disease. Cancer Cell 1:307-309.
14. Ebert, O., K. Shinozaki, T. G. Huang, M. J. Savontaus, A. Garcia-Sastre, and S. L. Woo. 2003. Oncolytic vesicular stomatitis virus for treatment of orthotopic hepatocellular carcinoma in immune-competent rats. Cancer Res. 63:3605-3611.
15. Fernandez, M., M. Porosnicu, D. Markovic, and G. N. Barber. 2002. Genetically engineered vesicular stomatitis virus in gene therapy: application for treatment of malignant disease. J. Virol. 76:895-904.
16. Graeber, T. G., C. Osmanian, T. Jacks, D. E. Housman, C. J. Koch, S. W. Lowe, and A. J. Giaccia. 1996. Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumours. Nature 379:88-91.
17. Harris, A. L. 2002. Hypoxia-a key regulatory factor in tumour growth. Nat. Rev. Cancer 2:38-47.
18. Hawkins, L. K., N. R. Lemoine, and D. Kirn. 2002. Oncolytic biotherapy: a novel therapeutic platform. Lancet Oncol. 3:17-26.
19. Hernandez-Alcoceba, R., M. Pihalja, D. Qian, and M. F. Clarke. 2002. New oncolytic adenoviruses with hypoxia- and estrogen receptor-regulated replication. Hum. Gene Ther. 13:1737-1750.
20. Hirasawa, K., S. G. Nishikawa, K. L. Norman, M. C. Coffey, B. G. Thompson, C. S. Yoon, D. M. Waisman, and P. W. Lee. 2003. Systemic reovirus therapy of metastatic cancer in immune-competent mice. Cancer Res. 63:348-353.
21. Hobbs, J. A., G. Hommel-Berrey, and Z. Brahmi. 2003. Requirement of caspase-3 for efficient apoptosis induction and caspase-7 activation but not viral replication or cell rounding in cells infected with vesicular stomatitis virus. Hum. Immunol. 64:82-92.
22. Hochachka, P. W., L. T. Buck, C. J. Doll, and S. C. Land, 1996. Unifying theory of hypoxia tolerance: molecular/metabolic defense and rescue mechanisms for surviving oxygen lack. Proc. Natl. Acad. Sci. USA 93:9493-9498.
23. Hockel, M., K. Schlenger, B. Aral, M. Mitze, U. Schaffer, and P. Vaupel. 1996. Association between tumor hypoxia and malignant progression in advanced cancer of the uterine cervix. Cancer Res. 56:4509-4515.
24. Huang, T. G., O. Ebert, K. Shinozaki, A. Garcia-Sastre, and S. L. Woo. 2003. Oncolysis of hepatic metastasis of colorectal cancer by recombinant vesicular stomatitis virus in immune-competent mice. Mol. Ther. 8:434-440.
25. Kopecky, S. A., and D. S. Lyles. 2003. The cell-rounding activity of the vesicular stomatitis virus matrix protein is due to the induction of cell death. J. Virol. 77:5524-5528.
26. Koshikawa, N., K. Takenaga, M. Tagawa, and S. Sakiyama. 2000. Therapeutic efficacy of the suicide gene driven by the promoter of vascular endothelial growth factor gene against hypoxic tumor cells. Cancer Res. 60:2936-2941.
27. Koumenis, C., C. Naczki, M. Koritzinsky, S. Rastani, A. Diehl, N. Sonenberg, A. Koromilas, and B. G. Wouters. 2002. Regulation of protein synthesis by hypoxia via activation of the endoplasmic reticulum kinase PERK and phosphorylation of the translation initiation factor eIF2α. Mol. Cell. Biol. 22:7405-7416.
28. Obuchi, M., M. Fernandez, and G. N. Barber. 2003. Development of recombinant vesicular stomatitis viruses that exploit defects in host defense to augment specific oncolytic activity. J. Virol. 77:8843-8856.
29. Perkins, D. J., and G. N. Barber. 2004. Defects in translational regulation mediated by the alpha subunit of eukaryotic initiation factor 2 inhibit antiviral activity and facilitate the malignant transformation of human fibroblasts. Mol. Cell. Biol. 24:2025-2040.
30. Post, D. E., and E. G. Van Meir. 2003. A novel hypoxia-inducible factor (HIF) activated oncolytic adenovirus for cancer therapy. Oncogene 22:2065-2072.
31. Probst, G., H. J. Riedinger, P. Martin, M. Engelcke, and H. Probst. 1999. Fast control of DNA replication in response to hypoxia and to inhibited protein synthesis in CCRF-CEM and HeLa cells. Biol. Chem. 380:1371-1382.
32. Rampling, R., G. Cruickshank, A. D. Lewis, S. A. Fitzsimmons, and P. Workman. 1994. Direct measurement of pO2 distribution and bioreductive enzymes in human malignant brain tumors. Int. J. Radiat. Oncol. Biol. Phys. 29:427-431.
33. Riedinger, H. J., M. van Betteraey, and H. Probst 1999. Hypoxia blocks in vivo initiation of simian virus 40 replication at a stage preceding origin unwinding. J. Virol. 73:2243-2252.
34. Riedinger, H. J., M. van Betteraey-Nikoleit, U. Hilfrich, K. H. Eisele, and H. Probst. 2001. Oxygen-dependent regulation of in vivo replication of simian virus 40 DNA is modulated by glucose. J. Biol. Chem. 276:47122-47130.
35. Sinkovics, J. G., and J. C, Horvath. 2000. Newcastle disease virus (NDV): brief history of its oncolytic strains. J. Clin. Virol. 16:1-15.
36. Stojdl, D. F., B. Lichty, S. Knowles, R. Mantis, H. Atkins, N. Sonenberg, and J. C. Bell. 2000. Exploiting tumor-specific defects in the interferon pathway with a previously unknown oncolytic virus. Nat. Med. 6:821-825.
37. Stojdl, D. F., B. D. Lichty, B. R. Tenoever, J. M. Paterson, A. T. Power, S. Knowles, R. Marius, J. Reynard, L. Poliquin, H. Atkins, E. G. Brown, R. K. Durbin, J. E. Durbin, J. Hiscott, and J. C. Bell. 2003. VSV strains with defects in their ability to shutdown innate immunity are potent systemic anti-cancer agents. Cancer Cell 4:263-275.
38. Tewari, M., L. T. Quan, K. O'Rourke, S. Desnoyers, Z. Zeng, D. R. Beidler, G. G. Poirier, G. S. Salvesen, and V. M. Dixit. 1995. Yama/CPP32 beta, a mammalian homolog of CED-3, is a CrmA-inhibitable protease that cleaves the death substrate poly(ADP-ribose) polymerase. Cell 81:801-809.
39. Volm, M., and R. Koomagi. 2000. Hypoxia-inducible factor (HIF-1) and its relationship to apoptosis and proliferation in lung cancer. Anticancer Res. 20:1527-1533.